Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 6Biliary Tract Neoplasms 5Rectal Neoplasms 3Colonic Neoplasms 3Gastrointestinal Stromal Tumors 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Piebaldism 1Pancreatic Neoplasms 1Locally Advanced Rectal Carcinoma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 9130-nm albumin-bound paclitaxel 6S 1 (combination) 4Albumin-Bound Paclitaxel 4toripalimab 3Taxes 3Nivolumab 2Injections 2Drug Therapy 2surufatinib 1penpulimab 1pegylated granulocyte colony-stimulating factor 1paricalcitol 1nimotuzumab 1irinotecan sucrosofate 1gimeracil 1fluzoparib 1envafolimab 1endostar protein 1conteltinib 1camrelizumab 1cabiralizumab 1apatinib 1Tegafur 1Simvastatin 1Radiosurgery 1Paclitaxel 1Oxaliplatin 1Metformin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Pancreatic Cancer × envafolimab × Gastrointestinal × Clear all
NCT05298020 2022-03-28

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

The Affiliated Hospital of Xuzhou Medical University

Phase 2 Unknown
20 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡